Healthcare -
Biotechnology - NASDAQ - US
$ 7.77
-5.08 %
$ 459 M
Market Cap
-2.82
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Cullinan Oncology, Inc.
| Net Income | -168 M |
| Depreciation & Amortization | 306 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 37.8 M |
| Change in Working Capital | -389 K |
| Others | -15 M |
| Free Cash Flow | -145 M |
Cash Flow
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||
| Net Income | (167.6) | (153.2) | 109.2 | (67.5) | (59.5) | (21.7) | (14.2) |
| Depreciation & Amortization | 0.3 | 0.3 | 93 K | 53 K | 62 K | 70 K | 43 K |
| Deferred Income Tax | 0 | 0 | 0 | 3.1 | 0.2 | 4 K | 0 |
| Stock Based Compensation | 37.8 | 30.4 | 28.0 | 24.4 | 14.9 | 17 K | 0 |
| Other Operating Activities | (15.5) | (11.5) | (275.1) | 67 K | 7.6 | 0.5 | 0.3 |
| Change in Working Capital | (0.4) | (0.3) | 11.2 | (3.5) | 6.9 | 0.1 | 0.3 |
| Cash From Operations | (145.3) | (134.3) | (126.7) | (43.4) | (29.8) | (20.9) | (13.5) |
| INVESTING CASH FLOW | |||||||
| Capital Expenditures | 0 | (0.2) | (1.1) | (0.6) | 10 K | 20 K | (0.3) |
| Other Items | (136.3) | 36.0 | 250.1 | (333.2) | (5.4) | (35.4) | 0 |
| Cash From Investing Activities | (136.3) | 35.8 | 249.0 | (333.8) | (5.4) | (35.4) | (0.3) |
| FINANCING CASH FLOW | |||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | (0.4) | 0 |
| Total Debt Repaid | 0 | 1.8 | (2.2) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.5 | 0.5 | (23.7) | 1.5 | 138.9 | 85.7 | 30 K |
| Cash From Financing Activities | 266.2 | 40.8 | (25.9) | 268.8 | 140.1 | 85.7 | 29 K |
| CHANGE IN CASH | |||||||
| Net Change In Cash | (15.4) | (57.7) | 96.4 | (108.4) | 104.9 | 29.4 | (13.8) |
| FREE CASH FLOW | |||||||
| Free Cash Flow | (145.3) | (134.5) | (127.8) | (44.0) | (29.8) | (20.9) | (13.8) |